Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Po-Ming Chow is a leading urologic oncologist whose research focuses on improving risk stratification and treatment outcomes for prostate cancer. His work centers on refining predictive tools for aggressive disease and optimizing therapeutic strategies for locally advanced cases. Dr. Chow’s major contributions include demonstrating that the Prostate Health Index (PHI) and its derivative %p2PSA can accurately predict adverse pathological outcomes in men undergoing radical prostatectomy, a finding with over 9 citations that aids in surgical planning. He also revealed a critical paradox: in high-grade, locally advanced prostate cancer, low initial PSA levels are paradoxically associated with more rapid disease progression, a study cited 8 times that challenges conventional screening assumptions. Furthermore, using propensity score matching, Dr. Chow’s research (7 citations) compared radical prostatectomy against radiotherapy with androgen deprivation therapy for T3/T4 disease, providing evidence to guide treatment selection. His work has been published in leading journals like *Scientific Reports* and *Cancers*, and he has been recognized with awards from the Taiwan Urological Association. Dr. Chow’s research directly impacts clinical decision-making, offering patients and surgeons more precise prognostic information and comparative effectiveness data for high-stakes treatment choices.